Dokumenttyp: journal article

Autor(en) des Beitrags:
von Minckwitz, G; Rezai, M; Fasching, P A; Huober, J; Tesch, H; Bauerfeind, I; Hilfrich, J; Eidtmann, H; Gerber, B; Hanusch, C; Blohmer, J U; Costa, S D; Jackisch, C; Paepke, S; Schneeweiss, A; Kümmel, S; Denkert, C; Mehta, K; Loibl, S; Untch, M

Titel des Beitrags:
Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40--GeparQuattro).

Abstract:
The GeparQuattro study showed that adding capecitabine or prolonging the duration of anthracycline-taxane-based neoadjuvant chemotherapy from 24 to 36 weeks did not increase pathological complete response (pCR) rates. Trastuzumab-treated patients with HER2-positive disease showed a higher pCR rate than patients with HER2-negative disease treated with chemotherapy alone. We here present disease-free (DFS) and overall survival (OS) analyses. Patients (n = 1495) with cT >= 3 tumors, or negative hormone-receptor status, or positive hormone-receptor and clinically node-positive disease received four times epirubicin/cyclophosphamide and were thereafter randomly assigned to four times docetaxel (Taxotere), or four times docetaxel/capecitabine over 24 weeks, or four times docetaxel followed by capecitabine over 36 weeks. Patients with HER2-positive tumors received 1 year of trastuzumab, starting with the first chemotherapy cycle. Follow-up was available for a median of 5.4 years. Outcome was not improved for patients receiving capecitabine (HR 0.92; P = 0.463 for DFS and HR 93; P = 0.618 for OS) as well as for patients...
receiving 36 weeks of chemotherapy (HR 0.97; P = 0.818 for DFS and HR 0.97; P = 0.825 for OS).
Trastuzumab-treated patients with HER2-positive disease showed similar DFS (P = 0.305) but a
significantly better adjusted OS (P = 0.040) when compared with patients with HER2-negative
disease treated with chemotherapy alone. Recorded long-term cardiac toxicity was low. Long-term
results, similar to the results of pCR, do not support the use of capecitabine in the neoadjuvant setting
in addition to an anthracycline-taxane-based chemotherapy. However, the results support previous
data showing a benefit of trastuzumab as predicted by higher pCR rates.